Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hV01 and Tislelizumab in Advanced Solid Tumors
NCT07185243Phase 1Recruiting
- Sponsor
- Hangzhou ConVerd Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of CVD-1301.V01 in solid tumor (advanced stage) (2 arms), sponsored by Hangzhou ConVerd Co., Ltd. Primary endpoints: Dose-limiting toxicities and Adverse events. Started Jun 2025; status: recruiting.
02
Drugs
CVD-1301.V01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07185243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185243.